0001781983 false 0001781983 2023-01-26 2023-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

January 26, 2023

Date of Report (Date of earliest event reported)

 

 

 

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-39069 84-2246769
(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     

3805 Old Easton Road

Doylestown, PA

(Address of principal executive offices)

 

18902

(Zip Code)

       

Registrant's telephone number, including area code: (617) 463-9385

 

(Former name or former address, if changed since last report):

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   

Name of each exchange on

which registered

Common stock, par value $0.001 per share   APRE   NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 8.01 Other Events.

 

On January 26, 2023, Aprea Therapeutics, Inc. (the “Company”) will be presenting at the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts. Copies of the presentation slide decks that the Company will use at the 6th Annual DDR Inhibitors Summit are filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are hereby incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit
Number

  

Description

99.1   Aprea Therapeutics, Inc. Presentation.
99.2   Aprea Therapeutics, Inc. Presentation.
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

  Aprea Therapeutics, Inc.
   
Dated: January 26, 2023 By: /s/ Oren Gilad

  Name: Oren Gilad
  Title: President and Chief Executive Officer

 

 

 

Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aprea Therapeutics Charts.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aprea Therapeutics Charts.